celldex therapeutics inc
(CLDX:NASDAQ GS)
celldex therapeutics inc (CLDX) Snapshot
|
Open
$15.48
|
Previous Close
$15.40
|
|
|
Day High
$15.60
|
Day Low
$15.10
|
|
|
52 Week High
06/12/13 - $16.48
|
52 Week Low
06/20/12 - $4.36
|
|
|
Market Cap
1.2B
|
Average Volume 10 Days
2.1M
|
|
|
EPS TTM
$-0.98
|
Shares Outstanding
80.9M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
celldex therapeutics inc (CLDX) Related Businessweek News
No Related Businessweek News Foundcelldex therapeutics inc (CLDX) Details
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
celldex therapeutics inc (CLDX) Top Compensated Officers
celldex therapeutics inc (CLDX) Key Developments
Celldex Therapeutics, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-05-2013 09:30 AM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Anthony S. Marucci, Chief Executive Officer, President and Director.
Celldex Therapeutics, Inc. has elected to prepay its term loans under its Loan and Security Agreement, dated as of December 30, 2010, by and among Celldex Therapeutics, Inc., Celldex Research Corporation, MidCap Financial, LLC, and General Electric Capital Corporation, as amended. pursuant to the terms of the Loan Agreement. Those term loans would have otherwise matured in December 2014. By prepaying the term loan in May 2013, the company will save approximately $0.5 million in interest expense, which would have been payable over the remaining term of the loan. On May 17, 2013, the company repaid in full its term loan under the MidCap Loan Agreement, repaying the remaining principal amount of approximately $8.8 million in addition to $0.7 million in interest, prepayment and final payment fees. As a result, the Loan Agreement was terminated. The company's obligations under the Loan Agreement had been secured by a first priority security interest in substantially all of its assets, other than its intellectual property. In connection with the termination of the Loan Agreement, those security interests are being released.
Celldex Therapeutics, Inc. Presents at Credit Suisse 2013 Antibody Day, May-10-2013 11:00 AM. Venue: New York, New York, United States. Speakers: Tibor Keller, Chief Scientific Officer and Senior Vice President.
| Recently Viewed | |||
| CLDX:US | $15.20 USD | -0.20 |  |
| Company | Last | Change | |
| No competitor information is available for CLDX. | |||
| View Industry Companies | |||
Industry Analysis
CLDX
Industry Average
| Valuation | CLDX | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Chicago, IL | DunnhumbyusaPosted: Jun 18
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
Sponsored Financial Commentaries
Sponsored Links
To contact CELLDEX THERAPEUTICS INC, please visit www.celldextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
